

Réanimation, infectiologie (ATB, candidose)

ID: 76

Rezafungin Treatment of Candidemia and Invasive Candidiasis: Outcomes Stratified by Baseline Renal Function–Analysis of the Phase 2 + Phase 3 Trials

J. Mira*(1), S.Taylor(2), J.Vasquez(3), A.Soriano(4)

(1) Médecine interne -Réanimation, Hôpital Cochin, Paris, France , (2) Direction médicale, CIDARA, San diego, United States , (3) Direction médicale, CIDARA, Augusta, United States , (4) Direction médicale, Hôpital Barcelona, Barcelone, Spain

**Auteur présenté comme orateur*

Position du problème et objectif(s) de l'étude:

Rezafungin (RZF) once weekly (QWk) is a next-generation echinocandin in development for treatment of candidemia and invasive candidiasis (IC) and prevention of invasive fungal disease caused by Candida, Aspergillus, and Pneumocystis spp. in BMT. RZF QWk was compared to caspofungin (CAS) QD in two double-blind, randomized, controlled trials of treatment of candidemia and/or IC: STRIVE (Phase 2, NCT02734862) and ReSTORE (NCT03667690).

Matériel et méthodes:

Trial data (Phase 2+Phase 3) were analyzed to evaluate outcomes stratified by renal function at baseline: CrCl ≥ 60 mL/min (normal/mild impairment [Norm/Mild]) and < 60 mL/min (moderate/severe impairment [Mod/Sev]).

Outcomes were evaluated for differences between CrCl categories and between treatment groups: RZF QWk 400mg on Wk 1 then 200 mg vs CAS QD 70 mg on Day (D)1 then 50mg, for ≥ 14 days (≤ 4 Wks) w/optional oral fluconazole stepdown for CAS.

Résultats & Discussion:

- D30 all-cause mortality (ACM)
 - o Mod/Sev: RZF, 13% (7/54); CAS, 30.5% (18/59)
 - o Norm/Mild: RZF, 22.7% (17/75); CAS, 10.8% (9/83)
- Mycological eradication (ME) at D5
 - o Mod/Sev: RZF, 75.9% (41/54); CAS, 61.0% (36/59)
 - o Norm/Mild: RZF, 74.7% (56/75); CAS, 66.3% (55/83)
- ME at D14
 - o Mod/Sev: RZF, 75.9% (41/54); CAS, 57.6% (34/59)
 - o Norm/Mild: RZF, 69.3% (52/75); CAS, 74.7% (62/83)
- ≥ 1 treatment-emergent AE
 - o Mod/Sev: RZF, 93.2% (55/59); CAS, 88.9% (56/63)
 - o Norm/Mild: RZF, 88.9% (72/81); CAS, 76.7% (69/90)

Conclusion:

RZF efficacy was comparable across CrCl categories, with higher ME and lower D30 ACM in Mod/Sev group. Further analyses are needed to evaluate the observed differences between treatment groups.

Les auteurs déclarent ne pas avoir toute relation financière impliquant l'auteur ou ses proches (salaires, honoraires, soutien financier éducationnel) et susceptible d'affecter l'impartialité de la présentation.